We are live on ! Find out more
PI

Pennant Investors Portfolio holdings

AUM $361M
1-Year Est. Return 134.26%
This Fund
S&P 500
This Quarter Est. Return
+13.33%
1 Year Est. Return
+134.26%
3 Year Est. Return
+359.01%
5 Year Est. Return
+289.76%
10 Year Est. Return
–
AUM
$383M
AUM Growth
-$21.1M
Cap. Flow
-$49.9M
Cap. Flow %
-13.03%
Top 10 Hldgs %
86.04%
Holding
51
New
6
Increased
1
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
MU icon
Micron Technology
MU
+$15.8M
2
VRT icon
Vertiv
VRT
+$10.5M
3
VMI icon
Valmont Industries
VMI
+$9.75M
4
GEV icon
GE Vernova
GEV
+$9.51M
5
IREN icon
Iris Energy
IREN
+$3.52M

Top Sells

Rank Stock Value
1
ENOV icon
Enovis
ENOV
+$25M
2
MSFT icon
Microsoft
MSFT
+$13.5M
3
TDG icon
TransDigm Group
TDG
+$12.3M
4
AMZN icon
Amazon
AMZN
+$10.3M
5
AR icon
Antero Resources
AR
+$9.71M

Sector Composition

Rank Sector Weight
1 Technology 25.38%
2 Industrials 19.02%
3 Communication Services 18.74%
4 Consumer Discretionary 16.23%
5 Energy 7.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ERAS icon
26
Erasca
ERAS
$6.39B
$392K 0.1%
166,200
– –
RCUS icon
27
Arcus Biosciences
RCUS
$3.64B
$361K 0.09%
23,700
– –
ETNB
28
DELISTED
89bio
ETNB
$356K 0.09%
44,500
– –
ZYME icon
29
Zymeworks
ZYME
$1.67B
$329K 0.09%
38,700
– –
ARCT icon
30
Arcturus Therapeutics
ARCT
$211M
$319K 0.08%
13,100
– –
ALLO icon
31
Allogene Therapeutics
ALLO
$694M
$299K 0.08%
128,400
– –
CHRS icon
32
Coherus Oncology
CHRS
$196M
$291K 0.08%
168,100
– –
RLAY icon
33
Relay Therapeutics
RLAY
$4.33B
$276K 0.07%
42,400
– –
REPL icon
34
Replimune Group
REPL
$1.01B
$275K 0.07%
30,500
– –
QURE icon
35
uniQure
QURE
$3.22B
$217K 0.06%
48,500
– –
MCRB icon
36
Seres Therapeutics
MCRB
$48.4M
$212K 0.06%
14,615
– –
CMPX icon
37
Compass Therapeutics
CMPX
$387M
$199K 0.05%
199,000
– –
SAGE
38
DELISTED
Sage Therapeutics
SAGE
$190K 0.05%
17,500
– –
GETR
39
DELISTED
Getaround, Inc.
GETR
$189K 0.05%
1,348,153
– –
MGNX icon
40
MacroGenics
MGNX
$257M
$186K 0.05%
43,800
– –
ALLK
41
DELISTED
Allakos
ALLK
$186K 0.05%
186,100
– –
KLRS
42
Kalaris Therapeutics
KLRS
$96.8M
$156K 0.04%
9,378
– –
ZNTL icon
43
Zentalis Pharmaceuticals
ZNTL
$302M
$133K 0.03%
32,400
– –
BTAI icon
44
BioXcel Therapeutics
BTAI
$27.8M
$107K 0.03%
5,244
– –
BLUE
45
DELISTED
bluebird bio
BLUE
$86K 0.02%
4,370
– –
GRABW icon
46
Grab Holdings Warrant
GRABW
$738K
$12.9K ﹤0.01%
80,000
– –
AAPL icon
47
PUT
Apple
AAPL
$4.57T
– –
-160,000
Closed -$27.4M
AGEN
48
Agenus
AGEN
$290M
– –
-23,480
Closed -$272K
ENOV icon
49
Enovis
ENOV
$1.53B
– –
-400,000
Closed -$25M
MIMO
50
DELISTED
Airspan Networks Holdings Inc
MIMO
– –
-1,047,473
Closed -$118K
1
2

Similar funds

BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return

Pennant Investors's Q2 2024 Portfolio in Review

As of Q2 2024, Pennant Investors held 51 positions worth $383M, down 5.2% from $404M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Pennant Investors withdrew a net $49.9M in Q2 2024, closing 5 positions and reducing 5 holdings. Its most notable exit was Enovis, an estimated $25M position sold in full.

By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 21% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Pennant Investors opened a new position in Vertiv worth $9.96M.

  • Pennant Investors's largest Q2 2024 buy was Vertiv: 115,000 shares worth $9.96M.
  • Pennant Investors added most to Micron Technology in Q2 2024, an estimated $15.8M increase.
  • Pennant Investors's biggest Q2 2024 reduction was Microsoft, cutting an estimated $13.5M.
  • Pennant Investors fully exited Enovis in Q2 2024, selling an estimated $25M.
  • Pennant Investors's ten largest holdings make up 86% of its $383M portfolio in Q2 2024.
  • Pennant Investors opened 6 new positions and closed 5 in Q2 2024.
  • Pennant Investors's portfolio value fell 5.2% quarter-over-quarter to $383M.

Based on Pennant Investors's 13F filing for Q2 2024, filed 14 Aug 2024.